(also called attacks or flares) but results in progressive joint damage. 4, 5 Left untreated, patients experience increasing frequency and longer duration of recurrent flares, impairment to kidney function, and deposition of urate crystals in the form of tophi within joints, tendons and under the skin. 6 Some patients are unable to perform daily tasks or remain gainfully employed, thus affecting economic productivity. 5 Singapore is a city-state in Southeast Asia, home to a population of 5.5 million. 7 The prevalence of gout in Singapore is 4.1%, higher than estimates in North America and Europe of between 1%-4%. 8, 9 Allopurinol, a highly effective xanthine-oxidase inhibitor is the firstline long-term urate-lowering therapy (ULT) for gout when attacks become recurrent or in the presence of tophi, arthritis, renal impairment or urolithiasis. 10 Reduction and maintenance of SU below 360 μmol/L prevent further gout attacks and promote tophi shrinkage. 6, 11, 12 Today, allopurinol remains the primary and most commonly prescribed option in Singapore (95%) for chronic management of gout due to lack of alternatives until the recent introduction of febuxostat. 13, 14 Uricosuric agents such as probenecid and benzbromarone are locally rarely used.
Long-term adherence to ULT limits the damaging impact of gout on daily living activities.
2,3,15
| Medication adherence: "Drugs don't work in patients who don't take them"
Poor or non-adherence counteracts the effectiveness of allopurinol and poses a major barrier to gout management. 6, 11, 16 A World Health
Organization report on adherence concluded that patients with chronic diseases are only on average 50% adherent in real-world settings. 17 More recently, medication adherence was compared across seven common chronic conditions including hypertension (72%), hypothyroidism (68%) and diabetes mellitus (65%), and reported that adherence levels were lowest in gout (37%). 18 The urgency to address this is compounded by a rapidly growing burden of disease, observed in Singapore and worldwide. 4 Only 24% of Singaporean patients on gout medication are highly adherent based on their Morisky Medication Adherence Scale-8
(MMAS-8) score, a validated patient self-report scale that has been found to reliably assess and predict patient medication-taking behavior. 19 Another local study based on clinical outcome measures (whether patients achieve target SU levels) found that only 25% of patients had controlled SU levels during 1 year of regular care. The authors cited poor patient adherence to allopurinol as a significant problem. 14 
| Determinants of medication non-adherence
Reasons for patients to forego medications as prescribed are complex, as non-adherence may be intentional or unintentional. [20] [21] [22] In
Bae et al's framework (Figure 1 ), patient beliefs about medicines and self-efficacy are proximal pathways to non-adherence, while sociodemographics, illness-related status, and polypharmacy are distal drivers. 20, 23 Distal factors are contextual characteristics of the patients that influence their cognition and beliefs, which in turn impact non-adherent behavior.
In Singapore's context, patient knowledge, beliefs, and attitudes toward ULT often predict non-adherence. 24 Traditionally, gout has been trivialized as a disease that does not impact mortality and morbidity. 13, 14, 24 Many view gout as episodic and mistakenly discontinue ULT after symptomatic treatment. 14 Perceived or experienced adverse effects also deter patients and prescribers, especially as ULT can trigger acute flares when first initiated. 11, 13, 19, 24, 25 Additionally, poor self-conviction in being able to successfully execute adherent behavior (ie low self-efficacy) has been linked to non-adherence.
11,26
Other significant predictors of non-adherence among
Singaporeans with gout include presence of comorbidities, patient marital status, and education level. 19, 24 Consistent with the published literature on gout, local patients with comorbidities tend to be more adherent. 6, 18 It has been suggested that patients who are more proficient in managing chronic conditions become better adherers. 6 Comorbidities also signal more life-threatening conditions that realign patient attitudes toward adherence. 19 Married individuals are also more likely adherent because of practical support from spouses in taking medication. 24, 27 Notably, gout patients with formal education in Singapore are found to be less adherent and possibly more critical of advice from their doctors. 19 
| Cost-effectiveness studies of adherenceenhancing interventions in gout
Only a handful of studies have evaluated the cost-effectiveness of investing in interventions that address non-adherence. Not surprisingly, none of them are in gout. [28] [29] [30] [31] In one systematic review, cost-effectiveness analyses (CEA) for 12 counselling adherence-enhancing interventions were inconclusive. Although 10/12 counselling interventions were highly cost-effective or cost-saving, there F I G U R E 1 Non-adherence framework adapted from Bae et al 20 were two interventions that were less effective and more costly than standard care ("dominated"). 
14,34
Data for matching variables were extracted from the PASS database for 111 intervention and 198 control patients. Demographics and SU were assessed on the index date: gout medications from 6 months prior, and comorbidities and hospitalization from 1 year prior to the index date. PSM was conducted using the MatchIt package in R (The R Foundation for Statistical Computing, http://www.r-project.org/). 35 We adopted a nearest-neighbor, 1-to-1 method of matching. 36 A "caliper" of 0.25 standard deviations, otherwise known as the maximum permitted distance between matched subjects, is commonly used and was thus chosen for the PSM. 37 Detailed methodology and assumptions used for patient selection and the PSM variables can be found in Appendix S1.
| Economic evaluation and decision tree analysis

| Design, perspective, and time horizon
A decision tree analysis was developed using TreeAge (TreeAge Software, Inc Williamstown, MA) to evaluate the incremental costeffectiveness of the intervention for gout patients attending NUH rheumatology compared to the other clinics. 14 Decision tree analysis was chosen over Markov modeling methods as the time horizon of the analysis was short and in the absence of repeated actions or with time-dependent events. 38 Cost analyses were evaluated in SGD then presented in USD, and effectiveness in quality-adjusted life years (QALYs). One SGD = 0.71 USD with the currency exchange rates on 10
April 2017. 39 In the base case, the societal perspective was used such that indirect costs significant in chronic diseases were included. The time horizon was 1 year, defined from the index date of the patient's first prescribed allopurinol. Sensitivity analysis was conducted for the hospital perspective and with an extended follow-up of 2 years.
| Intervention effect
The clinical database linked to the electronic medical records was reviewed for SU outcomes, defined as the last SU test value within the patient's follow-up period. Patients were stratified according to the degree to which they were treated-to-target. The intervention effect of the CPIP was measured by the percentage of patients at target (≤360 μmol/L) upon the end of follow-up in both groups. were excluded as earlier data from local rheumatoid arthritis patients showed that its contribution to societal cost was less than 2%. 40 Costs evaluated from the hospital's perspective were taken to be the sum of inpatient and outpatient direct costs. Indirect costs based on a human capital approach were included for societal perspective analyses, costing for lost income and the monetary value of employerpaid benefits lost during sick leave. 38 Details for costing of productivity losses and its assumptions can be found in Appendix S2. Inflation using Singapore's Consumer Price Index was applied to adjust costs to their 2016 values. 41 Discounting for costs and effects was not performed due to the short follow-up of 1 or 2 years. 38 Internal verification of costs was ensured by double programming for estimation of inpatient costs, with two programmers independently using R 3.2.5
and Stata 14.0 (StataCorp LLC, College Station, TX, USA). A Monte Carlo simulation of 10 000 iterations was used in a probabilistic sensitivity analysis (PSA). PSA was performed to check the simultaneous effect of uncertainty in the model. Using means and standard deviations taken for each of our clinical outcomes, we applied gamma distributions for cost variables and beta distributions for effects. A summary of parameter uncertainty was presented in a cost-effectiveness acceptability curve (CEAC). Given the cutoff WTP, the CEAC returns the probability of iterations wherein the results were cost-effective.
| Effects: Utilities and quality of life
| RE SULTS
| Propensity score matching
Propensity score matching (PSM) on nine variables resulted in 106 patients, with a sample of 53 in each group. Table 1 summarizes univariate tests of independence on baseline characteristics before and after PSM. Before matching, the intervention sample was significantly younger (P < 0.05), had more males (P < 0.01), higher use of NSAIDs, colchicine, glucocorticoids (P < 0.001), and more frequent gout admission history (P < 0.01). Controls were more often with comorbid conditions such as diabetes (P < 0.01) and chronic kidney disease (P < 0.05). The results of the PSM showed that differences in glucocorticoid use between groups remained marginally significant post-matching (P = 0.0448). No other variables at baseline were found to be statistically different between intervention and controls after matching.
| Economic evaluation and decision tree analysis
The decision tree was populated with costs, effects, and transition probabilities from PASS. The complete dataset for the model input can be found in Appendix S3. There were no missing values. For the intervention effect, 32% of rheumatology patients were treated-totarget by the end of 1 year, compared to 17% of controls from the other clinics.
| Base case analysis
The CPIP intervention was cost-effective with an ICER of $12 866 USD/QALY in the base case using the 1 year follow-up period and the societal perspective for analysis (Table 2) . Patients in the intervention group incurred higher cost in all three cost components (inpatient, outpatient, and productivity losses).
| Sensitivity analyses
All SA on model parameters produced ICERs below the chosen threshold value for cost-effectiveness. The key driver for cost-effectiveness based on Tornado analysis, that is the input parameter that leads to the most uncertainty in the ICER when varied, was inpatient cost ($4139-$21 593 USD/QALY). The least sensitive variable was outpatient cost ($12 798-$12 932 USD/QALY). Table 3 All results from the scenario analyses were below WTP threshold.
| Probabilistic sensitivity analysis
Mean incremental cost for 10 000 iterations of the ICER increased by $8 USD from the result in the base case analysis, but mean incremental effect remained unchanged (Table 4 ). The majority of the simulations showed positive incremental effectiveness, hence the F I G U R E 2 Decision tree model structure uncertainty relates largely to incremental cost. For greater precision, the proportion of iterations that were found to be cost-effective was determined over a range of WTP cutoffs and were presented using CEAC. The intervention had an 85% probability of being cost-effective at the threshold used in our analysis.
TA B L E 1 Baseline characteristics of intervention and control groups (A) before (top) and (B) after propensity score matching (bottom)
| D ISCUSS I ON
This study set out to retrospectively evaluate the cost-effectiveness of an adherence-enhancing intervention for Singaporean patients with gout, using real-world data. We replicated Lim et horizons tend to ignore a learning curve effect. 46 Health professionals learn to be more efficient over time, thus costs in the early stages of intervention may not be good predictors of costs in the long run. 38 At the same time, allopurinol's therapeutic effect is not immediate. Patients take a few months to feel its full benefits and may experience increased frequency of gout attacks when the drug is 1st initiated, delaying evidence of its effectiveness. 24, 25 The model was most sensitive to varying the inpatient cost parameter. The ICER was impacted the most if inpatient costs were further increased or decreased. One reason may be the wide confidence interval in the data from a small 6% of patients requiring gout-related hospitalizations, which contributed 15% to total societal cost. We observed that inpatient costs remained higher among intervention patients than for controls for the two follow-up durations. Despite matching for other illness-related determinants like SU and inpatient events at baseline, intervention patients may remain at a higher risk than controls to develop acute gout flares, given that rheumatology patients post-matching had significantly higher usage of glucocorticoids (Table 1) .
Nevertheless, these observations are based on a very small number of inpatient events.
Additionally, there was concern that using PSM to create balanced comparison groups selected for patients of overall lower gout severity and fewer comorbid conditions. The original treatment group had a higher mean gout hospitalization history and acute gout prescriptions, and controls had more comorbidities ( Charlson comorbidity index decreased from 1.23 to 0.66 to match fewer comorbidities seen in the intervention group. While this limits the CEA findings to a specific subgroup with gout, our findings remain relevant. Studies suggest that healthier patients adhere poorly due to relative inexperience in chronic disease management. 6, 47 A cost-effectiveness finding despite a low severity, low comorbidity, and possibly a less adherent patient population would strengthen the conclusion that the intervention has value for patients as well as the hospital. 24 Comparison of outcomes from this study and Lim et al's support that healthier patients of lower disease severity are poorer adherers.
The baseline proportion of intervention patients using NSAIDs was lower in our study which used PASS (11%), compared to Lim et al's recruited patients (44%). 14 Our patients were healthier, but Lim et al found a larger 31% increase (56% minus 25%) in the proportion of individuals achieving target SU due to CPIP, compared to our 15% (32% minus 17%). 14 Differences in disease severity notwithstanding, another explanation could be that selective participation and the opportunity for patients to refuse trial enrollment in the Lim et al study resulted in a more adherent population, and/or 1 that is more willing to become adherent. 
| Strengths and limitations
The study draws on the strengths of real-world evidence, use of PSM to successfully minimize important differences between groups and selection of a societal perspective to account for the wider economic burden to society. 14, 28, 38 Limitations include a small sample size and generalizability issues of our population at the tertiary hospital, although patients who meet indications for ULT in hospitals
should not differ from those in primary care. Utilities and the WTP threshold are dependent on other populations in the absence of locally established values. 42 We have adjusted for group differences on nine patient variables that the literature considered critical for gout, but PSM as a methodology has its inherent constraints in the event where residual confounders are left unmeasured, or where known confounders are imprecisely measured. For example, sociodemographic and economic variables including education, marital status, income, and insurance status are unavailable in PASS. The effect of unmeasured covariates that do not reside within patient records-whether known and unknown from the literature-cannot be evaluated. There should be clear attempts in future observational studies to measure and control for differences in patient characteristics, including sociodemographics and disease status, to avoid dilution of effects.
| CON CLUS ION
Through this study, considerable insight has been gained with regard to ULT adherence-enhancing interventions for long-term gout management. The cumulative results replicate reports of efficacy by Lim et al and provide robust evidence on its cost-effectiveness. To our knowledge, this is the first allopurinol adherence-enhancing intervention for which such an evidence base has been demonstrated and continued implementation of the program in routine clinical care is recommended. Its cost-effectiveness over the longer term should be evaluated.
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